Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Mar 26, 2025
Product Development
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report
Plus:
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Dec 19, 2024
Management Tracks
Bumpus leaving FDA
Plus: Ra Capital names three new partners and updates from Anaveon, Adicet, Bio Usawa and Neopredics
BioCentury | Oct 10, 2024
Discovery & Translation
Baker and DeepMind Nobel: Two sides of a computational protein coin
Protein design updates its engine: The field’s shift from physical models to deep learning
BioCentury | Sep 5, 2024
Data Byte
FDA’s new drug approvals in August include a Dupixent competitor, a targeted glioma therapy, and more
Agency approved seven new therapies in August, plus four new product formulations or dosages
BioCentury | Aug 16, 2024
Finance
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings
Plus: MeiraGTx, scPharmaceuticals each raise $50M
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | Apr 27, 2024
Discovery & Translation
Science spotlight: Tumor T cell restriction mechanism, plus programmable RNA excision
BioCentury’s roundup of translational innovations
BioCentury | Apr 18, 2024
Finance
Venture report: Metsera’s $290M launch, Regeneron’s new VC fund
Plus fundings for Asher, Pathios, Outrun and Theolytics
Items per page:
1 - 10 of 1237